Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 3.02p
   
  • Change Today:
      0.000p
  • 52 Week High: 7.76
  • 52 Week Low: 1.59
  • Currency: UK Pounds
  • Shares Issued: 333.40m
  • Volume: 9,400
  • Market Cap: £10.05m
  • RiskGrade: 328

Immupharma Overview

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -5491.7% n/a
ROCE n/a  
Latest F'cast
P/E 0.9 n/a
PEG n/a n/a
Pr/Revenue 83.8 n/a
Pr/Book 2.3  
Latest F'cast
Revenue -7.7% n/a
PBT n/a n/a
EPS -5.2% n/a
DPS n/a n/a

Immupharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 0.15 (7.00) (4.75)p n/a n/a n/a n/a 0.0%
31-Dec-18 0.08 (7.96) (5.19)p n/a n/a n/a n/a 0.0%
31-Dec-19 0.08 (6.74) (3.99)p n/a n/a n/a n/a 0.0%
31-Dec-20 0.13 (7.25) 3.43p 3.9 n/a n/a n/a 0.0%
31-Dec-21 0.12 (8.94) 3.25p 2.0 n/a -5% n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Immupharma Company Announcements

TR-1: Notification of major holdings 04-Jan-2023 17:26 RNS
Second Price Monitoring Extn 04-Jan-2023 16:40 RNS
Price Monitoring Extension 04-Jan-2023 16:35 RNS

Latest Immupharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Immupharma Market Data

Currency UK Pounds
Share Price 3.02p
Change Today 0.000p
% Change 0.00 %
52 Week High 7.76
52 Week Low 1.59
Volume 9,400
Shares Issued 333.40m
Market Cap £10.05m
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
72.23% above the market average72.23% above the market average72.23% above the market average72.23% above the market average72.23% above the market average
89.66% above the sector average89.66% above the sector average89.66% above the sector average89.66% above the sector average89.66% above the sector average
Price Trend
89.81% below the market average89.81% below the market average89.81% below the market average89.81% below the market average89.81% below the market average
70.97% below the sector average70.97% below the sector average70.97% below the sector average70.97% below the sector average70.97% below the sector average
Income Not Available
Growth
35.33% below the market average35.33% below the market average35.33% below the market average35.33% below the market average35.33% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average

Immupharma Dividends

No dividends found

Trades for 27-Jan-2023

Time Volume / Share Price
08:00 9,400 @ 3.20p

Immupharma Key Personnel

CEO Dimitri Dimitriou

Top of Page